aspirin has been researched along with Gastroesophageal Reflux in 50 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 7.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity." | 7.78 | Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012) |
| "There are several studies that suggest that aspirin (acetylsalicylic acid [ASA]) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with esophagitis or esophageal stricture formation." | 7.70 | NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? ( Davis, LP; Hunter, JG; Kim, SL; Waring, JP; Wo, JM, 1999) |
| " PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease." | 4.95 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017) |
| "Asthma has many triggers including rhinosinusitis; allergy; irritants; medications (aspirin in aspirin-exacerbated respiratory disease); and obesity." | 4.90 | Identifying asthma triggers. ( Ferguson, BJ; McCarty, JC, 2014) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 3.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity." | 3.78 | Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012) |
| " Male gender, smoking, alcohol drinking, consumption of coffee, large waist circumference, infrequent medication of antacids, aspirin and NSAIDs, infrequent and mild GERD symptoms were all significantly associated with ED on univariate analysis." | 3.77 | [Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors]. ( Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kim, SK; Kwon, JG; Lee, JH; Lee, SH; Lee, SJ; Park, CK; Park, KS; Seo, HE; Yang, CH, 2011) |
| "There are several studies that suggest that aspirin (acetylsalicylic acid [ASA]) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with esophagitis or esophageal stricture formation." | 3.70 | NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? ( Davis, LP; Hunter, JG; Kim, SL; Waring, JP; Wo, JM, 1999) |
| "Although low-dose acetylsalicylic acid (ASA) is recommended for prevention of cardiovascular events in at-risk patients, its long-term use can be associated with the risk of peptic ulcer and upper gastrointestinal (GI) symptoms that may impact treatment compliance." | 2.78 | Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. ( Agewall, S; Herlitz, J; Lanas, A; Nagy, P; Nauclér, EC; Scheiman, JM; Svedberg, LE; Veldhuyzen van Zanten, SJ, 2013) |
| "15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily." | 2.77 | Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. ( Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012) |
| " Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day." | 2.75 | Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010) |
| "Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin." | 2.53 | Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016) |
| "Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas." | 2.47 | Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011) |
| "In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis." | 2.43 | [Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005) |
| "Gastroesophageal reflux disease has a high incidence of 23%, with 29% of those with gastroesophageal reflux disease consuming nonsteroidal anti-inflammatory drugs." | 1.72 | In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium. ( Bor, S; Çağanoğlu, D; Ergün, P; Kıpçak, S, 2022) |
| " In study 2, 35 healthy subjects were treated with LDA 100 mg (regimen A), and then 20 randomly selected subjects were dosed clopidogrel 75 mg (regimen C), LDA/clopidogrel (regimen AC), or LDA/clopidogrel/rabeprazole 10 mg for 7 days." | 1.39 | Antiplatelet drugs are a risk factor for esophageal mucosal injury. ( Furuta, T; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2013) |
| "Risk factors associated with GERD were identified by logistic regression analysis in respondents who were not taking aspirin or proton pump inhibitors." | 1.35 | Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. ( Barthélémy, P; Ruszniewski, P; Soufflet, C, 2008) |
| " We assessed the presence of duration-response and dose-response effects." | 1.34 | Chronic proton pump inhibitor therapy and the risk of colorectal cancer. ( Hennessy, S; Hwang, WT; Lewis, JD; Propert, K; Sedarat, A; Yang, YX, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (12.00) | 18.7374 |
| 1990's | 1 (2.00) | 18.2507 |
| 2000's | 17 (34.00) | 29.6817 |
| 2010's | 23 (46.00) | 24.3611 |
| 2020's | 3 (6.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kıpçak, S | 1 |
| Çağanoğlu, D | 1 |
| Ergün, P | 1 |
| Bor, S | 1 |
| Kamal, H | 1 |
| Sadr-Azodi, O | 1 |
| Engstrand, L | 2 |
| Brusselaers, N | 2 |
| Hatakeyama, Y | 1 |
| Horino, T | 1 |
| Matsumoto, T | 1 |
| Terada, Y | 1 |
| Okuhara, Y | 1 |
| Wahlin, K | 1 |
| Lagergren, J | 1 |
| Sugisaki, N | 1 |
| Iwakiri, R | 1 |
| Tsuruoka, N | 1 |
| Sakata, Y | 1 |
| Shimoda, R | 1 |
| Fujimoto, S | 1 |
| Eguchi, Y | 1 |
| Fujimoto, K | 1 |
| Sugimoto, M | 3 |
| Uotani, T | 2 |
| Nishino, M | 3 |
| Yamade, M | 3 |
| Sahara, S | 1 |
| Yamada, T | 1 |
| Osawa, S | 1 |
| Sugimoto, K | 1 |
| Umemura, K | 1 |
| Watanabe, H | 1 |
| Miyajima, H | 1 |
| Furuta, T | 3 |
| Steppuhn, H | 1 |
| Langen, U | 1 |
| Scheidt-Nave, C | 1 |
| Keil, T | 1 |
| Kim, SG | 1 |
| Jung, HK | 1 |
| Lee, HL | 1 |
| Jang, JY | 1 |
| Lee, H | 1 |
| Kim, CG | 1 |
| Shin, WG | 1 |
| Shin, ES | 1 |
| Lee, YC | 1 |
| McCarty, JC | 1 |
| Ferguson, BJ | 1 |
| Cowie, A | 1 |
| Noble, F | 1 |
| Underwood, T | 1 |
| Esquivias, P | 1 |
| Cebrián, C | 1 |
| Morandeira, A | 1 |
| Santander, S | 1 |
| Ortego, J | 1 |
| García-González, MA | 1 |
| Lanas, A | 2 |
| Piazuelo, E | 1 |
| Goldberg, A | 1 |
| Gerkin, RD | 1 |
| Young, M | 1 |
| Thrift, AP | 2 |
| Anderson, LA | 1 |
| Murray, LJ | 1 |
| Cook, MB | 1 |
| Shaheen, NJ | 2 |
| Rubenstein, JH | 1 |
| El-Serag, HB | 1 |
| Vaughan, TL | 1 |
| Schneider, JL | 1 |
| Whiteman, DC | 2 |
| Corley, DA | 1 |
| Zou, D | 1 |
| Goh, KL | 2 |
| Raschi, E | 1 |
| Bianchin, M | 1 |
| Poluzzi, E | 1 |
| De Ponti, F | 1 |
| Ruszniewski, P | 1 |
| Soufflet, C | 1 |
| Barthélémy, P | 1 |
| Pandeya, N | 1 |
| Webb, PM | 1 |
| Sadeghi, S | 1 |
| Green, AC | 1 |
| Kodaira, C | 2 |
| Ikuma, M | 2 |
| Tanaka, T | 1 |
| Sugimura, H | 1 |
| Hishida, A | 1 |
| Seite, F | 1 |
| Delelis-Fanien, AS | 1 |
| Valero, S | 1 |
| Pradère, C | 1 |
| Poupet, JY | 1 |
| Ingrand, P | 1 |
| Paccalin, M | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Martín de Argila de Prados, C | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Lee, SJ | 1 |
| Jung, MK | 1 |
| Kim, SK | 1 |
| Jang, BI | 1 |
| Lee, SH | 1 |
| Kim, KO | 1 |
| Kim, ES | 1 |
| Cho, KB | 1 |
| Park, KS | 1 |
| Kim, EY | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Lee, JH | 1 |
| Yang, CH | 1 |
| Park, CK | 1 |
| Seo, HE | 1 |
| Jeon, SW | 1 |
| Nicholson, A | 1 |
| Jankowski, J | 2 |
| Selvan, B | 1 |
| Ramachandran, A | 1 |
| Korula, A | 1 |
| Amirtharaj, GJ | 1 |
| Kettimuthu, K | 1 |
| Nair, S | 1 |
| Nair, A | 1 |
| Samuel, P | 1 |
| Mathew, G | 1 |
| Scheiman, JM | 1 |
| Herlitz, J | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Agewall, S | 1 |
| Nauclér, EC | 1 |
| Svedberg, LE | 1 |
| Nagy, P | 1 |
| Wepner, U | 1 |
| Laheij, RJ | 2 |
| Van Rossum, LG | 1 |
| Jansen, JB | 2 |
| Verheugt, FW | 2 |
| Füessl, HS | 2 |
| Singh, G | 1 |
| Koop, H | 1 |
| Bazzoli, F | 1 |
| Kinoshita, Y | 1 |
| Yuki, T | 1 |
| Malfertheiner, P | 1 |
| Fass, R | 1 |
| Quigley, EM | 1 |
| Modlin, IM | 1 |
| Malagelada, JR | 1 |
| Moss, SF | 1 |
| Holtmann, G | 1 |
| Katelaris, P | 1 |
| Stanghellini, V | 1 |
| Talley, NJ | 1 |
| Tytgat, GN | 1 |
| Wright, NA | 1 |
| Leedham, S | 1 |
| Ferrara, M | 1 |
| Coppola, L | 1 |
| Coppola, A | 1 |
| Capozzi, L | 1 |
| Slavin, RG | 1 |
| Yang, YX | 1 |
| Hennessy, S | 1 |
| Propert, K | 1 |
| Hwang, WT | 1 |
| Sedarat, A | 1 |
| Lewis, JD | 1 |
| Kim, SL | 1 |
| Hunter, JG | 1 |
| Wo, JM | 1 |
| Davis, LP | 1 |
| Waring, JP | 1 |
| Verbeek, AL | 1 |
| Dyck, WP | 1 |
| Smith, VM | 1 |
| Siegel, SC | 1 |
| Rachelefsky, GS | 1 |
| Phillips, SF | 1 |
| Ramirez-Mata, M | 1 |
| Reyes, PA | 1 |
| Alarcon-Segovia, D | 1 |
| Garza, R | 1 |
| Berman, PM | 1 |
| Kirsner, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727] | Phase 3 | 2,426 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 591 |
| Esomeprazole 20 mg | 577 |
| Placbo | 504 |
RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 mg | 554 |
| Esomeproazole 20 mg | 537 |
| Placebo | 451 |
(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 40 | 214 |
| Esomeproazole 20 | 213 |
| Placebo | 380 |
The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.1 |
| Esomeproazole 20 | 0.75 |
| Placebo | 4.1 |
The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 1.35 |
| Esomeproazole 20 | 1 |
| Placebo | 6.58 |
The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Esomeprazole 40 | 0.24 |
| Esomeproazole 20 | 0.25 |
| Placebo | 2.73 |
13 reviews available for aspirin and Gastroesophageal Reflux
| Article | Year |
|---|---|
Identifying asthma triggers.
Topics: Allergens; Aspirin; Asthma; Disease Progression; Female; Gastroesophageal Reflux; Humans; Male; Prog | 2014 |
Strategies to improve outcomes in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi | 2014 |
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres | 2016 |
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi | 2017 |
Acid reflux and oesophageal cancer.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas | 2011 |
Understanding NSAID-PPI-COX-2 interrelationships.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida | 2004 |
[Medical treatment of Barrett's esophagus].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo | 2005 |
Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Gastrins; Gastroesoph | 2006 |
Dilemmas in managing Barrett's oesophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Endoscopy, Gastrointestinal; Ga | 2006 |
Iron deficiency in childhood and adolescence: retrospective review.
Topics: Adolescent; Anemia, Iron-Deficiency; Animals; Aspirin; Cattle; Celiac Disease; Child; Child, Prescho | 2006 |
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De | 2007 |
Continuing medical education. Asthma in infants and children: Part 1.
Topics: Airway Resistance; Allergens; Aspirin; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Child, Pres | 1985 |
Pathophysiology of gastritis: recent concepts and clinical significance.
Topics: Aspirin; Bile; Ethanol; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Gastroscopy; Humans; Sto | 1972 |
4 trials available for aspirin and Gastroesophageal Reflux
| Article | Year |
|---|---|
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid | 2010 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; | 2012 |
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Topics: Age Factors; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, | 2013 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
33 other studies available for aspirin and Gastroesophageal Reflux
| Article | Year |
|---|---|
In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Epithelium; Gastroesophageal Reflux; Huma | 2022 |
Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile | 2021 |
Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal | 2021 |
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Gastro | 2017 |
A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Case-Control Studies; | 2018 |
Antiplatelet drugs are a risk factor for esophageal mucosal injury.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Aspirin; Case-Control Studies; Clopidogrel; | 2013 |
Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Comorbidity; Cross-Sectional Studies; Emergency Service, H | 2013 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal | 2013 |
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea | 2014 |
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Calcium; Case-Control Stu | 2015 |
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont | 2016 |
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution.
Topics: Aspirin; Cardiovascular Diseases; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Proton Pu | 2017 |
Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female | 2008 |
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2010 |
Compliance with guidelines for proton pump inhibitor prescriptions in a department of geriatrics.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Prescriptions; Femal | 2009 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
[Security of proton pump inhibitors].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Drug Interactions; | 2011 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors].
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2011 |
Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blotting, Western; Caspase 3; | 2012 |
[A case for proton pump blocker... When cough comes from the stomach].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Age | 2002 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
[Helicobacter pylori: changes of indications for eradication therapy].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Gastroesophageal Reflu | 2004 |
Definitions and classification of dyspepsia: pH, Helicobacter pylori, non-steroidal anti-inflammatory drugs--should we include gastro-oesophageal reflux disease?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastroesophageal Reflux; Helicobacter I | 2005 |
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent | 2007 |
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colore | 2007 |
[Family practice highlights of stomach, liver and intestinal reference points. Your arsenal against abdominal problems].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Family Practi | 2007 |
NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus?
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Esophage | 1999 |
Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease.
Topics: Aspirin; Calcium Channel Blockers; Deglutition Disorders; Dyspepsia; Fibrinolytic Agents; Flatulence | 2001 |
Pathophysiologic considerations in peptic ulcer disease.
Topics: ABO Blood-Group System; Adrenal Cortex Hormones; Aspirin; Bicarbonates; Environment; Female; Gastric | 1979 |
Association of aspirin ingestion with symptomatic esophageal hiatus hernia.
Topics: Aspirin; Barium Sulfate; Esophagitis, Peptic; Esophagogastric Junction; Esophagus; Gastroesophageal | 1978 |
Esophageal motility in systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Aspirin; Azathioprine; Chloroquine; Deglutition Disorders; Dilatation; Drug | 1974 |
Recognizing and avoiding adverse gastrointestinal effects of drugs.
Topics: Aged; Antacids; Aspirin; Colon; Digestive System; Drug Antagonism; Drug Interactions; Drug-Related S | 1974 |